基因沉默突发新闻 Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infectionsnucleonics公司得到fda关开始第一阶段试验表达rnai的办法治疗慢性乙肝病毒感染 May 2 2007, 9:15 AM EST2007年5月2日,上午09点15分东部时间 Business Wire商业新闻 Nucleonics, Inc., a biotechnology company focused on the development of novel expressed interfering RNA (eiRNA) based therapeutics, announced today that it has received clearance from the US Food and Drug Administration for its Investigational New Drug (IND) application to begin a Phase 1 human safety study of Nucleonics' investigational eiRNA therapy for the treatment of chronic hepatitis B (HBV) infection.nucleonics公司,该公司是一家生物技术公司,专注于开发新型表达干扰核糖核酸方法(eirna)根据疗法今天宣布,它已收到了手续,由美国食品和药物管理局,其在研新药(移民局)应用展开第一阶段人体安全性研究nucleonics的侦查eirna疗法治疗慢性肝炎乙(乙型肝炎病毒)感染. This clearance paves the way for the company to begin treating patients in June.这一关铺平了道路,公司开始治疗6. A total of 15 patients will be enrolled in the study, which will be conducted in the United States and Europe.共有15名患者将参加研究将进行的,在美国和欧洲. "We are very pleased to be able to move forward with this human safety study, which will be the first systemic delivery of an RNAi therapeutic to patients," said Robert Towarnicki, Nucleonics, Inc. president and chief executive officer."我们很高兴可以继续前进,这对人体是安全的研究这将是首次系统性交付的rnai治疗病人,"roberttowarnicki说nucleonics公司公司总裁兼首席执行官. "Our approach, which simultaneously targets four different regions of the HBV genome, offers the opportunity to destroy all of the different RNA molecules produced by HBV within an infected cell through RNA interference. Therefore, if successful, it could offer a significantly more potent antiviral therapy than has ever before been achieved.""我们的方针,目标,同时进行四个不同地区的乙肝病毒基因提供机会给毁掉一切不同核糖核酸分子产生内乙型肝炎病毒感染的细胞通过核糖核酸干扰.所以,如果成功的话,它可以提供一个更加显着的烈性病毒疗法比以往取得的." About Nucleonics HBV Candidate对乙肝的nucleonics候选人 Nucleonics employs an expressed interfering RNA (eiRNA) approach whereby scientists insert plasmid DNA coding for relevant short hairpin RNAs (shRNA) into targeted cells, inducing the cells to produce and deliver specific shRNA sequences.nucleonics公司表示,分子干扰核糖核酸方法(eirna)方法,科学家插入质粒编码有关短发夹核糖核酸(短发夹)植入目标细胞中,让细胞产生并传递特定的shrna序列. Nucleonics' researchers have shown the ability of shRNA produced in this way to silence genes, including Hepatitis B, Hepatitis C, and HIV, in relevant cell lines for extended periods of time.nucleonics的研究已显示出他们有能力短发夹这种方式产生的基因沉默,其中包括乙型肝炎,丙型肝炎,艾滋病毒,在相关细胞株很长时间. Moreover, they have silenced multiple genes in adult mice without triggering an interferon response.此外,他们还沉默多种基因在成年小鼠产生干扰素反应. Nucleonics' product pipeline includes eiRNA therapeutics directed against chronic Hepatitis B, Hepatitis C, pan-influenza (including H5N1 avian flu), as well as prostate and ovarian cancer.nucleonics的成品油管道包括eirna疗法针对慢性乙肝,丙肝,泛流感(包括禽流感),以及前列腺癌和卵巢癌. The Nucleonics' HBV clinical candidate encodes four short hairpin RNA (shRNA) molecules, each under the control of an RNA polymerase III promoter.该nucleonics的乙型肝炎临床候选四个编码短发夹核糖核酸(短发夹)分子每个控制下的一种核糖核酸聚合酶三子. Each of the four shRNAs targets a different segment of the HBV genome and collectively they mediate the destruction of all the different RNA molecules produced by HBV within an infected cell through RNAi.每年4rnai对象不同,部分乙肝病毒基因和集体调解销毁所有不同核糖核酸分子产生乙肝病毒在感染细胞中,通过针. Extensive characterization of this vector has shown that each shRNA contributes significantly to the potent antiviral effect of the vector in infected cells.广泛表征向量这表明每个发夹状大大有助于烈性抗载体在受感染的细胞. Moreover, the ability to provide four different shRNAs from a single expression vector greatly reduces the potential for viral resistance to develop.此外,能够提供四种不同rnai从单一表达载体大大减少潜在的病毒抗药性发展. About Nucleonics, Inc.约nucleonics公司,公司 Nucleonics, founded in January 2001, is an emerging biotechnology company focused on the development of novel RNA interference-based therapeutics for viral and other diseases.nucleonics公司成立于2001年1月是一个新兴的生物技术公司,专注于开发新型核糖核酸干扰型疗法用于治疗病毒性及其他疾病. Privately owned Nucleonics is headquartered in Horsham, Pennsylvania.民营nucleonics公司总部设在宾夕法尼亚州的horsham. | 
楼主: 木百
发表于 2007-6-16 05:24
